GlassScriptPhysician profile
Joann Reyes
NPI 1255970141
$4,394.65
in general payments reported to CMS, 2019-2025
24 companies · $2,507 in 2025
The $2,507 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $19.81 · 2023: $59.60 · 2024: $1,808 · 2025: $2,507.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,336 · Travel and Lodging: $39.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,335.55 |
| Travel and Lodging | $39.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $2,121.36 | 2024-2025 | Apretude, Dovato, Cabenuva |
| Otsuka America Pharmaceutical, INC. | $311.01 | 2024-2025 | Rexulti |
| Gilead Sciences, INC. | $307.85 | 2025 | Biktarvy |
| Madrigal Pharmaceuticals | $297.90 | 2025 | Rezdiffra |
| Novartis Pharmaceuticals Corporation | $235.44 | 2024-2025 | |
| Novo Nordisk INC | $180.69 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $179.12 | 2025 | Pifeltro, Capvaxive |
| Amgen INC. | $144.17 | 2024-2025 | Otezla, Repatha |
| Lilly USA, LLC | $117.89 | 2025 | Zepbound, Mounjaro |
| Corcept Therapeutics | $61.33 | 2025 | Korlym |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $60.39 | 2025 | Caplyta |
| Theratechnologies INC. | $59.55 | 2025 | Trogarzo, Egrifta |
| Napo Pharmaceuticals INC | $51.68 | 2024-2025 | Mytesi |
| Hologic Sales and Service, LLC | $44.44 | 2023 | Aptima |
| Takeda Pharmaceuticals U.S.A., INC. | $35.99 | 2024-2025 | Trintellix |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $27.61 | 2025 | Spravato |
| Teva Pharmaceuticals USA, INC. | $27.15 | 2024 | Uzedy |
| Axsome Therapeutics, INC. | $24.21 | 2024 | Auvelity |
| Exact Sciences Corporation | $23.10 | 2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $19.81 | 2022 | |
| Noven Therapeutics, LLC | $19.08 | 2025 | Xelstrym |
| Emd Serono, INC. | $15.95 | 2024 | |
| Organon LLC | $15.16 | 2023 | Nexplanon |
| Abbvie INC. | $13.77 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joann Reyes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.